

Medicine, Nursing and Health Sciences

# Biomedicine Discovery Seminar

Monash Biomedicine Discovery Institute in conjunction with  
Monash Partners Comprehensive Cancer Consortium



## Breast Cancer Treatment, Tumor biology and Metastasis



Thursday 10 November 2016




12.00 – 1.00 pm



Level 3 Seminar Room  
15 Innovation Walk  
Clayton campus

### Abstract

Today's talk will discuss advancements in the development of novel clinical trials for the treatment of breast cancer with a special focus on the efficacy of new immunotherapeutic strategies applied in combination with targeted therapies



### Presenter

**Assoc. Professor Sherene Loi**

MBBS (Hons), FRACP, PhD

Peter MacCallum Cancer Centre, Melbourne

### About the presenter

A/Prof Loi is a medical oncologist specializing in the treatment of breast cancer. She leads a research lab that focuses on genomics and novel therapeutics in breast cancer, particularly understanding the genomic and immune interface in breast cancer patients. Her interest is also the development of novel therapeutics in the preclinical and clinical space. In preclinical models, A/Prof Loi and colleagues have shown that combination immunotherapy with anti-HER2 therapy has synergistic effects and as a result, a phase II trial testing the efficacy of immunotherapy with trastuzumab is currently ongoing.

A/Prof Loi completed her medical oncology training in Melbourne, Australia. She worked in Brussels, Belgium, at the Breast International Group clinical trials headquarters for nearly 8 years before returning to the Peter MacCallum Cancer Centre in Melbourne, Australia where her breast cancer practice and lab are located. She is also an active member of the Scientific Advisory Committee of the Australian and New Zealand Breast Cancer Trials Group (ANZBCTG) and co-chairs the Translational Working Group of the International Breast Cancer Study Group (IBCSG). She is the current holder of the Cancer Council Victoria John Colebatch Clinical Fellowship.



**MONASH** University



Monash Partners Comprehensive Cancer Consortium